The ESMO Deep Dive - Lower Digestive Cancers Webinar Series recordings and slides are available to all ESMO Members.
ESMO Deep Dive: Lower Digestive Cancers - Insights from Biology and Clinical Research in the Management of Patients with Molecularly-Defined Subgroups of Metastatic Colorectal Cancers 2023
![ESMO-Deep-Dive-Lower-Digestive-Webinars-Metastatic-1000x250](/var/esmo/storage/images/media/esmo/meetings/2023/_webinars/webinar-series/esmo-deep-dive-upper-digestive-cancers/esmo-deep-dive-lower-digestive-webinars-metastatic-1000x250/17270537-1-eng-GB/esmo-deep-dive-lower-digestive-webinars-metastatic-1000x250.jpg)
It is with great pleasure that I invite you to participate in the ESMO webinar on Deep Dive into Lower Digestive Cancers that will provide insights from biology and clinical research in the management of patients with molecularly-defined subgroups of metastatic colorectal cancers.
This webinar is developed with the aim to acquire a deeper understanding of the clinical course of malignant disease of the lower digestive system and understand biological hypotheses on classification and risk stratification, ongoing/required research in therapeutics and knowledge of use of omics technologies for biomarker-enabled precision medicine for lower digestive cancers. Furthermore, the programme will enhance development of skills and abilities for critical analysis, interpretation of research data and therapeutic strategies, as well as becoming better equipped for informed, innovative thinking and engagement in ongoing or new research projects.
I am delighted to announce the distinguished speakers who will join me in this webinar. We will discuss, in turn, metastatic colorectal cancer patients bearing HER2 molecular aberrations, BRAF mutations, RAS G12C, G12D and G12V mutations, and lastly patients bearing rare molecular aberrations: ALK, ROS, NTRK, NRG1, PolE-PolD. The lectures will be followed by live discussion by speaker’s panel.
The programme is designed to provide an overview of the state of the art and ongoing research in therapies for patients with metastatic colorectal cancer. It will offer expert opinion exchange and provide some important considerations for practice and research in this field. I strongly encourage and invite you to register and join us all in this new ESMO activity.
Prof. Clara Montagut
Hospital del Mar, Barcelona, Spain
Pompeu Fabra University, Barcelona, Spain
Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
Speakers
Programme
Time |
Title |
Speaker |
---|---|---|
5 min |
Welcome and Introduction |
Clara Montagut |
20 min |
Patients with mCRC bearing HER2 molecular aberrations |
Andrea Sartore-Bianchi |
20 min |
Patients with mCRC bearing BRAF mutations |
Julien Taieb |
20 min |
Patients with mCRC bearing RAS G12C, G12D and G12V mutations |
Dominik Paul Modest |
20 min |
Patients with mCRC bearing rare molecular aberrations: ALK, ROS, NTRK, NRG1, PolE-PolD |
Elena Élez |
15 min |
LIVE Q&A |
All |
A certificate of attendance and 2 ESMO-MORA category 1 points will be awarded for live attendance at this event
Learning objectives:
- To acquire a deeper understanding of the clinical course of malignant disease of the lower digestive system
- To understand biological hypotheses on classification and risk stratification, ongoing/required research in therapeutics and knowledge of use of omics technologies for biomarker-enabled precision medicine for Lower Digestive Cancers
- To develop skills and abilities for critical analysis, interpretation of research data and therapeutic strategies
- To become better equipped for informed, innovative thinking and engagement in ongoing or new research projects